technology
OpenAI acquires Orchestra Bio to connect AI research with drug development
OpenAI says it has acquired Orchestra Bio and will bring its drug-development coordination platform together with Rosalind, its AI tools for life-sciences research. The company aims to build agents that help teams connect scientific findings with the studies and decisions needed to advance potential medicines.